Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Am J Cardiol. 2008 May 2;102(1):64–69. doi: 10.1016/j.amjcard.2008.02.097

Figure 2.

Figure 2

Comparison of treatment-associated changes (post minus baseline) in fasting lipid and lipoprotein concentrations among the fenofibrate (FEN), rosiglitazone (RSG), or a calorie-restricted diet (CRD) groups.

p value indicates significance of difference among the 3 groups by one-way ANOVA. *Tukey’s pairwise comparisons: A) FEN vs. RSG (p=0.01); C) RSG vs. FEN (p=0.003) and RSG vs. CRD (p=0.001); and D) CRD vs. RSG (p=0.03).